HSP72 demonstrated significant metabolic protection against obesity-induced insulin resistance by inhibiting JNK inflammatory signalling and enhancing mitochondrial oxidative capacity, providing a new target for the treatment of type 2 diabetes and related complications. This evidence concerns the gene MAPK8 and type 2 diabetes mellitus.